about
Hepatic steatosis: a benign disease or a silent killerA New Twist to a Chronic HCV Infection: Occult Hepatitis CSerendipitous identification of natural intergenotypic recombinants of hepatitis C in IrelandEvolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759Analysis of Ribavirin Mutagenicity in Human Hepatitis C Virus InfectionNuclear factors are involved in hepatitis C virus RNA replicationIdentification of Novel Epoxide Inhibitors of Hepatitis C Virus Replication Using a High-Throughput ScreenHepatitis C Virus Induces E6AP-Dependent Degradation of the Retinoblastoma ProteinGenetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus RibavirinComparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase InhibitorsCombinations of Cyclophilin Inhibitor NIM811 with Hepatitis C Virus NS3-4A Protease or NS5B Polymerase Inhibitors Enhance Antiviral Activity and Suppress the Emergence of ResistanceEnhanced anti-HCV activity of interferon alpha 17 subtypeDeterminants of Hepatitis C Virus p7 Ion Channel Function and Drug Sensitivity Identified In VitroTargeting host factors: A novel rationale for the management of hepatitis C virusThe Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus ReplicationAmphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral EntryMultiple effects of Honokiol on the life cycle of hepatitis C virusAn integrated transcriptomic and meta-analysis of hepatoma cells reveals factors that influence susceptibility to HCV infectionMechanisms of activity and inhibition of the hepatitis C virus RNA-dependent RNA polymerase.Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase.Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entryHepatitis C virus: virology, diagnosis and management of antiviral therapy.Controversies in and challenges to our understanding of hepatitis C.Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limitsTupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection.Occurrence of genetic modifications in core, 5'UTR and NS5b of HCV associated with viral response to treatment.Prospective Evaluation of FIBROSpect II for Fibrosis Detection in Hepatitis C and B Patients Undergoing Laparoscopic Biopsy.New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agentsInhibition of hepatitis C virus 3a genotype entry through Glanthus Nivalis Agglutinin.Effect of vitamin D therapy on interleukin-6, visfatin, and hyaluronic acid levels in chronic hepatitis C Egyptian patientsNew developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assaysImproving anti-hepatitis C virus therapy.Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV--focus on pegylated interferon-alpha.Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patientsCompletion of the Entire Hepatitis C Virus Life Cycle in Vero Cells Derived from Monkey Kidney.Capacity enhancement of hepatitis C virus treatment through integrated, community-based care.Immune responses during acute and chronic infection with hepatitis C virus.Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C.Prospects of RNAi and microRNA-based therapies for hepatitis C.
P2860
Q22305506-E2446DB2-4775-4FE5-BF00-5737F0CD6243Q26798189-83F8E84F-5755-44B8-9491-6DDA9911C82CQ27477682-2B372D15-FFFA-46E2-A755-CABB914235BFQ27480267-A49A05BB-2682-40BE-842B-F982BFCF83CAQ27480933-129EC04C-3F58-495D-91A2-01EAACA8B8A9Q27481075-4A34F906-44D5-48BE-B9F7-EB3FE88FEB69Q27481404-905A0FCF-E657-49FE-8865-EEA15D8C8495Q27485880-C8B6475B-2A13-45DE-BCA8-3AA1CF8C59E9Q27486648-6864CD8A-458A-486B-BFDA-8937A94ACD68Q27486813-F92F439E-BF09-4EC0-BFC0-9122F95D0BD7Q27486821-E4DC2977-F53A-49CE-9C0F-9A016F627DBFQ27488764-BAA1CEAC-47BC-47B0-B1EC-B676BBEC7D22Q27488995-46392F1E-E5E1-44EF-8C4F-6E107C3531D8Q27488999-9FE7ED0E-D2CB-422A-B073-63015B6B9C82Q27489053-BEEDB11E-7D43-427D-9E67-8F0170945D5DQ27490785-4D75F69B-CB8A-46E1-A0C7-2EB0BA6FE5E6Q28253400-938FD7FB-8761-4A29-B458-CFC735491BBAQ28743482-AFD68DDA-F18D-481A-8399-FAF70A2C2863Q30318760-8234B951-3881-4089-A995-0EE7C6D6192FQ33972367-9944372F-F102-48D3-9CC6-A22E8391B68CQ34062532-4044D2DA-723C-4BCD-976C-764332053E54Q34098547-274DB90D-5B8F-4B36-8322-5FC1DCB3CB22Q34604806-07D26E67-E739-4443-95A4-EBB12A57E6DFQ34741602-09F29ACB-7F1E-43FC-A67D-32D0D0AC2533Q34742966-92C85033-24A5-4674-95C1-7AE2A2509BD1Q34896257-F31A2F89-514B-4882-8B9B-1C64723B7827Q34996766-4B97263C-1CF1-4590-97AA-C088D2715EE0Q35026553-8D4EFDB3-AF61-4330-9218-0574CEB9E5F5Q35053124-FB2822E4-ECDF-404A-8C96-350B9A0B267CQ35130052-16137EB8-619D-46E7-BAB5-8C174547EA40Q35653358-7E03521D-31D6-468C-B0C8-787A943F3E32Q36022842-F8CA9698-1111-43AD-AB2C-E0DD19809950Q36569749-5B80318F-61AF-49BD-AA85-860D65D6886FQ36920320-B71E08D7-F04F-442F-9DF3-43F9DE2D5B04Q36983527-CB35450D-F474-49F9-8C1F-5D6606E9BEEBQ37027285-8E8C9A6B-E5A4-4170-9FDC-D13A8C22A060Q37136533-E25E4724-C466-4E01-B697-2387E2750B48Q37178225-386E0ABC-7BDF-4EDE-8D7F-7B3692D3F70CQ37181381-B11974EA-B18F-4005-A59B-2D378A45859DQ37489877-6B95A726-498E-43E8-9B81-F2615572BC5D
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Therapy of hepatitis C: from empiricism to eradication.
@ast
Therapy of hepatitis C: from empiricism to eradication.
@en
type
label
Therapy of hepatitis C: from empiricism to eradication.
@ast
Therapy of hepatitis C: from empiricism to eradication.
@en
prefLabel
Therapy of hepatitis C: from empiricism to eradication.
@ast
Therapy of hepatitis C: from empiricism to eradication.
@en
P2860
P356
P1433
P1476
Therapy of hepatitis C: from empiricism to eradication.
@en
P2093
Jean-Michel Pawlotsky
P2860
P304
P356
10.1002/HEP.21064
P407
P433
P577
2006-02-01T00:00:00Z